131 related articles for article (PubMed ID: 21376263)
1. Efficacy and safety of radiotherapy in acromegaly.
González B; Vargas G; Espinosa-de-los-Monteros AL; Sosa E; Mercado M
Arch Med Res; 2011 Jan; 42(1):48-52. PubMed ID: 21376263
[TBL] [Abstract][Full Text] [Related]
2. Guidelines for the diagnosis and treatment of acromegaly: a Canadian perspective.
Patel YC; Ezzat S; Chik CL; Rorstad OP; Serri O; Ur E; Wilkins GE
Clin Invest Med; 2000 Jun; 23(3):172-87. PubMed ID: 10911548
[TBL] [Abstract][Full Text] [Related]
3. Medical therapy in patients with acromegaly: predictors of response and comparison of efficacy of dopamine agonists and somatostatin analogues.
Sherlock M; Fernandez-Rodriguez E; Alonso AA; Reulen RC; Ayuk J; Clayton RN; Holder G; Sheppard MC; Bates A; Stewart PM
J Clin Endocrinol Metab; 2009 Apr; 94(4):1255-63. PubMed ID: 19158203
[TBL] [Abstract][Full Text] [Related]
4. Pituitary gland: Medical therapy for acromegaly: can we predict response?
Giustina A; Porcelli T
Nat Rev Endocrinol; 2009 Aug; 5(8):425-7. PubMed ID: 19629067
[TBL] [Abstract][Full Text] [Related]
5. McCune-Albright syndrome and acromegaly: effects of hypothalamopituitary radiotherapy and/or pegvisomant in somatostatin analog-resistant patients.
Galland F; Kamenicky P; Affres H; Reznik Y; Pontvert D; Le Bouc Y; Young J; Chanson P
J Clin Endocrinol Metab; 2006 Dec; 91(12):4957-61. PubMed ID: 16984995
[TBL] [Abstract][Full Text] [Related]
6. Conventional pituitary irradiation is effective in lowering serum growth hormone and insulin-like growth factor-I in patients with acromegaly.
Jenkins PJ; Bates P; Carson MN; Stewart PM; Wass JA
J Clin Endocrinol Metab; 2006 Apr; 91(4):1239-45. PubMed ID: 16403824
[TBL] [Abstract][Full Text] [Related]
7. Somatostatin analogs as a first-line treatment in acromegaly: when is it appropriate?
Grasso LF; Pivonello R; Colao A
Curr Opin Endocrinol Diabetes Obes; 2012 Aug; 19(4):288-94. PubMed ID: 22627686
[TBL] [Abstract][Full Text] [Related]
8. Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study.
Colao A; Cappabianca P; Caron P; De Menis E; Farrall AJ; Gadelha MR; Hmissi A; Rees A; Reincke M; Safari M; T'Sjoen G; Bouterfa H; Cuneo RC
Clin Endocrinol (Oxf); 2009 May; 70(5):757-68. PubMed ID: 19178516
[TBL] [Abstract][Full Text] [Related]
9. Biochemical assessment and long-term monitoring in patients with acromegaly: statement from a joint consensus conference of the Growth Hormone Research Society and the Pituitary Society.
;
J Clin Endocrinol Metab; 2004 Jul; 89(7):3099-102. PubMed ID: 15240576
[No Abstract] [Full Text] [Related]
10. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study.
Plöckinger U; Quabbe HJ
Acta Neurochir (Wien); 2005 May; 147(5):485-93; discussion 493. PubMed ID: 15806331
[TBL] [Abstract][Full Text] [Related]
11. Treatment of acromegaly.
Holdaway IM
Horm Res; 2004; 62 Suppl 3():79-92. PubMed ID: 15539805
[TBL] [Abstract][Full Text] [Related]
12. Conventional and novel biomarkers of treatment outcome in patients with acromegaly: discordant results after somatostatin analog treatment compared with surgery.
Rubeck KZ; Madsen M; Andreasen CM; Fisker S; Frystyk J; Jørgensen JO
Eur J Endocrinol; 2010 Nov; 163(5):717-26. PubMed ID: 20813787
[TBL] [Abstract][Full Text] [Related]
13. Growth hormone response to oral glucose before and after transfrontal pituitary surgery and radiotherapy in acromegaly.
Dash RJ; Saini JS; Chander S; Kak VK; Ayyagari S
J Assoc Physicians India; 1986 Mar; 34(3):171-3. PubMed ID: 3015867
[No Abstract] [Full Text] [Related]
14. The PPAR-gamma activator rosiglitazone fails to lower plasma growth hormone and insulin-like growth factor-1 levels in patients with acromegaly.
Bastemir M; Akin F; Yaylali GF
Neuroendocrinology; 2007; 86(2):119-23. PubMed ID: 17671378
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of acromegaly in Aarhus University Hospital. A retrospective investigation of the period from 1994 to 2004].
Madsen M; Matthiesen EB; Poulsen PL; Weeke J; Astrup J; Jørgensen JO
Ugeskr Laeger; 2007 Mar; 169(10):907-10. PubMed ID: 17359734
[TBL] [Abstract][Full Text] [Related]
16. Predictors of outcome following Gamma Knife surgery for acromegaly.
Poon TL; Leung SC; Poon CY; Yu CP
J Neurosurg; 2010 Dec; 113 Suppl():149-152. PubMed ID: 21222293
[TBL] [Abstract][Full Text] [Related]
17. [Acromegaly--diagnosis and treatment].
Bollerslev J
Tidsskr Nor Laegeforen; 2000 Sep; 120(21):2534-8. PubMed ID: 11070991
[TBL] [Abstract][Full Text] [Related]
18. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly.
Ayuk J; Clayton RN; Holder G; Sheppard MC; Stewart PM; Bates AS
J Clin Endocrinol Metab; 2004 Apr; 89(4):1613-7. PubMed ID: 15070920
[TBL] [Abstract][Full Text] [Related]
19. Combined treatment of somatostatin analogues with pegvisomant in acromegaly.
Franck SE; Muhammad A; van der Lely AJ; Neggers SJ
Endocrine; 2016 May; 52(2):206-13. PubMed ID: 26661938
[TBL] [Abstract][Full Text] [Related]
20. Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy.
Colao A; Pivonello R; Galderisi M; Cappabianca P; Auriemma RS; Galdiero M; Cavallo LM; Esposito F; Lombardi G
J Clin Endocrinol Metab; 2008 Jul; 93(7):2639-46. PubMed ID: 18445662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
